US To Purchase 600K Additional Doses of GSK-Vir's COVID-19 Antibody Therapy

By Vandana Singh

The U.S. has agreed to buy 600,000 more doses of GlaxoSmithKline plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy for an undisclosed sum.

  • The companies would supply the additional doses of sotrovimab to the U.S. in Q1 of 2022, taking the tally of doses secured by nations worldwide to roughly 1.7 million.
  • The U.S. government in November had signed contracts worth about $1 billion for an unknown number of doses of the treatment after saying it would control the distribution of sotrovimab.
  • Related: Glaxo-Vir Biotech's Antibody Approved In Europe For Early Treatment Of COVID-19.
  • GSK and Vir said they expect to produce roughly 2 million doses of sotrovimab globally in 1H of 2022.
  • Price Action: VIR stock is down 0.42% at $33.28, while GSK shares are up 0.28% at $44.97 during the market session on the last check Tuesday.

What is inkl?

Important stories

See news based on value, not advertising potential. Get the latest news from around the world.

Trusted newsrooms

We bring you reliable news from the world’s most experienced journalists in the most trusted newsrooms.

Ad-free reading

Read without interruptions, distractions or intrusions of privacy.